Advances in MRI assessment of gliomas and response to anti-VEGF therapy. - Test2 - elhamkhani - TriplyDB

Advances in MRI assessment of gliomas and response to anti-VEGF therapy.

Advances in MRI assessment of gliomas and response to anti-VEGF therapy.

http://www.wikidata.org/entity/Q33793253

about

Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center study Opportunities and challenges for successful use of bevacizumab in pediatrics.Translational imaging endpoints to predict treatment response to novel targeted anticancer agents.Antiangiogenic therapy of brain tumors: the role of bevacizumab.Imaging biomarkers for antiangiogenic therapy in malignant gliomas.Post-treatment imaging changes in primary brain tumors.Pros and cons of current brain tumor imaging Vascular endothelial growth factor blockade alters magnetic resonance imaging biomarkers of vascular function and decreases barrier permeability in a rat model of lung cancer brain metastasis.Advanced neuroimaging in the clinic: critical appraisal of the evidence base.MRI biomarkers identify the differential response of glioblastoma multiforme to anti-angiogenic therapy.The use of longitudinal 18F-FET MicroPET imaging to evaluate response to irinotecan in orthotopic human glioblastoma multiforme xenografts Tryptophan PET-defined gross tumor volume offers better coverage of initial progression than standard MRI-based planning in glioblastoma patients Prognostic value of CD109+ circulating endothelial cells in recurrent glioblastomas treated with bevacizumab and irinotecan.Hypervascular tumor volume estimated by comparison to a large-scale cerebral blood volume radiographic atlas predicts survival in recurrent glioblastoma treated with bevacizumab.18F-FET microPET and microMRI for anti-VEGF and anti-PlGF response assessment in an orthotopic murine model of human glioblastoma.Accuracy of percentage of signal intensity recovery and relative cerebral blood volume derived from dynamic susceptibility-weighted, contrast-enhanced MRI in the preoperative diagnosis of cerebral tumours Functional imaging: what evidence is there for its utility in clinical trials of targeted therapies?Response assessment in recurrent glioblastoma treated with irinotecan-bevacizumab: comparative analysis of the Macdonald, RECIST, RANO, and RECIST + F criteria.Differentiation of pseudoprogression and real progression in glioblastoma using ADC parametric response maps.Detection of glioblastoma response to temozolomide combined with bevacizumab based on μMRI and μPET imaging reveals [18F]-fluoro-L-thymidine as an early and robust predictive marker for treatment efficacy.Tryptophan PET in pretreatment delineation of newly-diagnosed gliomas: MRI and histopathologic correlates Early post-bevacizumab progression on contrast-enhanced MRI as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 Central Reader Study A systematic pipeline for the objective comparison of whole-brain spectroscopic MRI with histology in biopsy specimens from grade III glioma.Misleading early blood volume changes obtained using ferumoxytol-based magnetic resonance imaging perfusion in high grade glial neoplasms treated with bevacizumab.Posttreatment DSC-MRI is Predictive of Early Treatment Failure in Children with Supratentorial High-Grade Glioma Treated with Erlotinib.Perfusion MRI as the predictive/prognostic and pharmacodynamic biomarkers in recurrent malignant glioma treated with bevacizumab: a systematic review and a time-to-event meta-analysis.Measurable Supratentorial White Matter Volume Changes in Patients with Diffuse Intrinsic Pontine Glioma Treated with an Anti-Vascular Endothelial Growth Factor Agent, Steroids, and Radiation.Anatomical specificity of vascular endothelial growth factor expression in glioblastomas: a voxel-based mapping analysis.Bevacizumab for malignant gliomas: current indications, mechanisms of action and resistance, and markers of response.Integrative Analysis of mRNA, microRNA, and Protein Correlates of Relative Cerebral Blood Volume Values in GBM Reveals the Role for Modulators of Angiogenesis and Tumor Proliferation.Differentiation between treatment-related changes and progressive disease in patients with high grade brain tumors using support vector machine classification based on DCE MRI.Whole-brain spectroscopic MRI biomarkers identify infiltrating margins in glioblastoma patients.Perfusion of surgical cavity wall enhancement in early post-treatment MR imaging may stratify the time-to-progression in glioblastoma.Dynamic contrast-enhanced perfusion processing for neuroradiologists: model-dependent analysis may not be necessary for determining recurrent high-grade glioma versus treatment effect.Hypoxic cell waves around necrotic cores in glioblastoma: a biomathematical model and its therapeutic implications.High-Throughput Quantification of Phenotype Heterogeneity Using Statistical Features.Recurrent high-grade glioma treated with bevacizumab: prognostic value of MGMT methylation, EGFR status and pretreatment MRI in determining response and survival.Response assessment of bevacizumab in patients with recurrent malignant glioma using [18F]Fluoroethyl-L-tyrosine PET in comparison to MRI.Early response evaluation for recurrent high grade gliomas treated with bevacizumab: a volumetric analysis using diffusion-weighted imaging.Nonlinear registration of diffusion-weighted images improves clinical sensitivity of functional diffusion maps in recurrent glioblastoma treated with bevacizumab.

P2860

Q30413713-D0B626DC-B620-413D-8D19-14E72B58C7CA Q30454883-7C963D56-CEBC-4580-8B0B-717E1CEBA537 Q30465097-FEA2E4AE-24CC-4377-825F-3CDCF502D48E Q30737224-B19FB9F6-71E5-4A05-8473-659A00A42706 Q30764736-FB0C92C9-54E4-455E-B9DC-4DF6C25E8A5D Q30835236-9C6771F7-846B-4165-A430-2C7204BAE6D4 Q30860126-5EC67095-122F-4FC9-ADAE-476643ADF821 Q30934034-A08EBA65-26AA-4C78-A6FA-51D5E3044C76 Q31076319-640AC963-C771-4AD3-9E8C-D9397EFA33D5 Q33616649-71DED887-D7CB-4391-B893-A64F3A572D10 Q33740417-97019C9C-6CD2-4850-B120-DD0AE0B313AF Q34533978-D16C270A-83FD-4610-A0C3-BED18C910B14 Q34999120-A591C833-C3C7-4EE3-9719-59491405D214 Q35093286-FED34182-06DE-445C-9B0A-FF9703E04B00 Q35094941-54A1B2F2-CB66-42DC-BE4E-C5E65362636C Q35811181-41C06512-ABF5-426F-AEDF-33817B9B30E4 Q35879814-4FA15B21-1A05-4791-90BB-9CAE035E11B2 Q35914535-6C4587A1-A39A-4137-B100-E27B663D4E2A Q36337934-2BC7CC5D-9002-4C06-B8D1-419195A68910 Q36500372-1A58F7B6-E020-41F4-BA6B-8BAA56AA6A9F Q36644371-CAEA792C-F49E-47AB-B3E3-ACDA674810C4 Q36943907-FDA51A81-6558-4B99-9F5F-BDFBE7AC9568 Q37143167-11862D08-DAA2-4287-92A4-BD64B26BCCCB Q37523107-11A156AE-CC6F-4CC4-B7C9-9299A8D96019 Q38734338-D3C1E8FC-7661-4A3A-8302-2EDA45E9ED9D Q38815926-DC0A9202-1F7C-4475-93A4-0D0E96D52431 Q38827788-18B8A07B-7693-4729-A8C8-4A500AB6E3D6 Q38954802-37DFE71F-9E9E-4260-85CA-88EB0E542589 Q39225820-5C3417C1-0144-442E-A01A-83BFCCBCF414 Q39692548-5BB4CDC1-BC5B-401B-A381-9437C0FD301E Q40120047-B5381B12-D973-43C3-9EDF-CE858C2C5A39 Q40360133-D4B85E6B-DD48-4C08-87DB-9EA543E99946 Q41090550-5CD51B21-127A-46CF-88E2-594DC64DF93A Q41698852-F538D76F-19F4-4B68-9FA7-B1C7E7963EA0 Q41883885-3DED35DC-0220-40BA-8770-B913F8B89C07 Q42091011-8BEB97C5-20C4-431B-BB35-0FDC1BB84455 Q44362904-BE68BA3E-92AF-4C85-888C-07DB06639B9B Q44461998-057F2C60-DCB2-4A5B-A5A9-C47DA86E8FB3 Q45951765-D66506A4-8B2E-419E-B992-3BC80CC32DE8 Q46438150-61E7EEBA-8803-4E0C-879F-8760E9D45F73

P2860

Advances in MRI assessment of gliomas and response to anti-VEGF therapy.

http://www.wikidata.org/entity/Q33793253

description

2011 nî lūn-bûn

@nan

2011 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Advances in MRI assessment of gliomas and response to anti-VEGF therapy.

@ast

Advances in MRI assessment of gliomas and response to anti-VEGF therapy.

@en

type

label

Advances in MRI assessment of gliomas and response to anti-VEGF therapy.

@ast

Advances in MRI assessment of gliomas and response to anti-VEGF therapy.

@en

prefLabel

Advances in MRI assessment of gliomas and response to anti-VEGF therapy.

@ast

Advances in MRI assessment of gliomas and response to anti-VEGF therapy.

@en

P1433

Q33793253-A5844890-C26A-4593-883E-A305C91BBB4F

P1476

Q33793253-0C1A1C73-2F5C-4029-9ACB-00C522985862

P2093

Q33793253-604CD556-A8AA-4454-9CD7-08E03442AC4F

P2860

Q33793253-0B62CCCA-F212-4AE3-B603-57BCD38A77C5

Q33793253-11FCC8B5-C9C6-4217-9405-35C1BF178D3F

Q33793253-1E7785DD-11EE-437A-9EC3-0A5A35049AD5

Q33793253-2BDDF5C9-D4DA-4758-8BEB-2B45202E1F54

Q33793253-2F3710A0-9F16-4DD8-BEFF-DEA2F9B677BD

Q33793253-36BA5ED6-5750-47AD-B46E-3F0E9BAB16C6

Q33793253-3928BADA-3231-45B8-BC58-0639457D52E3

Q33793253-3A402B9F-C044-496C-BDF9-1CFC2317CAED

Q33793253-3EB7E32B-8503-4415-B819-E533DEDE76F7

Q33793253-479EE2F3-1AD6-4943-9800-F2082B1B4826

P2888

Q33793253-B6BB36C7-891F-4E6C-8D67-D82A9DE03261

P304

Q33793253-006C4C92-F49D-4A38-B6B2-E910415520CE

P31

Q33793253-23353365-2C68-4A39-A5BE-82225A9D643C

Q33793253-6D7639C0-3106-4E8E-A443-F295EBC12077

P356

Q33793253-9205BFF5-108F-47DF-B57E-528D344BA04C

P433

Q33793253-A734327B-1BC4-47D6-A432-F4E089833CE7

P478

Q33793253-240F4049-FCDE-4B6C-8061-6944DB5D197B

P50

Q33793253-D3F53179-9A46-47B3-94C8-7302A723F7BE

Q33793253-E1DEDA3A-FDB5-4B14-AC44-37680146C848

P577

Q33793253-75A70835-F9CF-49BC-9F95-3CDCDB4AEC46

P5875

Q33793253-613C12A5-2559-4B98-A655-DA68FBEF0592

P6179

Q33793253-F67EA42A-E8B2-45C9-B039-FBFF5446DA37

P698

Q33793253-E4251E88-8F25-4E63-A6FC-FA6887F58DA0

P921

Q33793253-67CD8471-AB5E-42D3-B9EA-E172FA9DB3C5

Q33793253-F3C941B7-EDDE-4054-906E-F3ABAA260228

P932

Q33793253-DA7F712C-17D3-465D-8DB1-E308CC57B4FB

P356

S11910-011-0179-X

P1433

Current Neurology and Neuroscience Reports

P1476

Advances in MRI assessment of gliomas and response to anti-VEGF therapy.

@en

P2093

Whitney B Pope

http://www.w3.org/2001/XMLSchema#string

P2860

A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients.

Evaluation of the functional diffusion map as an early biomarker of time-to-progression and overall survival in high-grade glioma.

The functional diffusion map: an imaging biomarker for the early prediction of cancer treatment outcome.

Comparison of dynamic susceptibility-weighted contrast-enhanced MR methods: recommendations for measuring relative cerebral blood volume in brain tumors

Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice.

Pseudoprogression and pseudoresponse: challenges in brain tumor imaging.

Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment.

Pseudoprogression and pseudoresponse in the treatment of gliomas.

Differentiation of recurrent glioblastoma multiforme from radiation necrosis after external beam radiation therapy with dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging

Glioblastoma: a method for predicting response to antiangiogenic chemotherapy by using MR perfusion imaging--pilot study.

P2888

s11910-011-0179-x

P304

336-344

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11910-011-0179-X

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P50

Jonathan R Young

Benjamin M Ellingson

P577

2011-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49755196

http://www.w3.org/2001/XMLSchema#string

P6179

1031469818

http://www.w3.org/2001/XMLSchema#string

P698

21234719

http://www.w3.org/2001/XMLSchema#string

P921

P932

3075404

http://www.w3.org/2001/XMLSchema#string